Dosing & Uses
Dosage Forms & Strengths
inhalation solution
- 75mg/single-use vial
Cystic Fibrosis (CF)
Indicated to improve respiratory symptoms in patients with CF infected with Pseudomonas aeruginosa
75 mg inhaled q8hr for 28 days; use only with Alterna nebulizer; do not repeat for 28 days after completion
Doses should be administered at least 4 h apart
Use bronchodilator before administration; administer short-acting beta agonists 15 min to 4 h before or long-acting beta agonists 30 min to 12 h before
If taking mucolytics, take after bronchodilators, but before aztreonam
Reconstitution and Storage
Store vials and diluent refrigerated at 2-8 degrees C (36-46 degrees F)
Once removed from refrigerator, may store at room temperature (up to 25 degree C; 77 degrees F) for up to 28 days
Use immediately upon reconstitution; do not reconstitute more than 1 dose at a time
Dosage Forms & Strengths
inhalation solution
- 75mg/single-use vial
Cystic Fibrosis (CF)
Indicated to improve respiratory symptoms in patients with CF infected with Pseudomonas aeruginosa
<7 years: Safety/efficacy not established
>7 years: As adults, 75 mg inhaled q8hr for 28 days; use only with Alterna nebulizer; do not repeat for 28 days after completion
Doses should be administered at least 4 h apart
Use bronchodilator before administration; administer short-acting beta agonists 15 min to 4 h before or long-acting beta agonists 30 min to 12 h before
If taking mucolytics, take after bronchodilators, but before aztreonam
Adverse Effects
>25%
Cough (54%)
10-25%
Nasal congestion ( 16%)
Wheezing (16%)
Pharyngolaryngeal pain (12%)
Pyrexia (13%)
1-10%
Chest discomfort (8%)
Abdominal pain (7%)
Vomiting (6%)
Bronchospasm (3%)
Rash (2%)
Warnings
Contraindications
Hypersensitivity
Cautions
Allergic reactions observed in clinical trials, stop treatment if allergic reaction occurs
May cause bronchospasm, stop treatment if chest tightness develops during nebulizer use
Increases FEV1 during 28-day course, consider baseline FEV1 when evaluating whether post-treatment changes in FEV1 are caused by pulmonary exacerbation
Increased risk of drug-resistant bacteria in absence of known Pseudomonas aeruginosa
Pregnancy & Lactation
Pregnancy
Available data on use in pregnant women is insufficient to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; however, systemic absorption of aztreonam following inhaled administration is expected to be minimal
There are risks to the mother associated with cystic fibrosis in pregnancy; cystic fibrosis may increase the risk for preterm delivery
Animal data
- In animal reproduction studies with aztreonam for injection administered parenterally to pregnant rats and rabbits during organogenesis, there was no evidence of developmental toxicity; a peri/postnatal study in rats revealed no drug-induced changes in maternal, fetal, or neonatal parameters
Lactation
Following intravenous administration, drug is excreted in human milk at concentrations that are less than one percent of those determined in simultaneously obtained maternal serum
Peak plasma concentrations of aztreonam following administration of 75 mg are approximately 1% of peak concentrations observed following IV administration (500 mg); systemic absorption of aztreonam following inhaled administration is expected to be minimal; there are no data on effects of drug on breastfed infant or effects on milk production.
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for therapy and any potential adverse effects on the breastfed infant from drug or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Inhibits cell wall synthesis by binding to penicillin binding protein 3, which in turn inhibits cell wall biosynthesis; member of monobactam family
Pharmacokinetics
Half-Life: 1.7 hr (children); 1.7-2.9 hr (adults)
Absorption: Low systemic absorption
Mean Plasma Concentration: 0.59 mcg/mL (1 hr after single dose, approximately the peak plasma conc); 0.55 mcg/mL, 0.67 mcg/mL, 0.65 mcg/mL (1 hr after multiple doses on days 1, 14, and 28 respectively); in contrast, plasma concentration following 500 mg IV is 54 mcg/mL
Mean Sputum Concentration: 726 mcg/g (after single dose); 984 mcg/g, 793 mcg/g, 715 mcg/g (10 min after multiple doses on days 1, 14, and 28 respectively)
Peak Plasma Time: Approximately 1 hr
Protein Bound: 56%
Excretion: Urine (60-70%); feces (13-15%)
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Cayston inhalation - | 75 mg/mL nebulizer soln |  |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
